17 February 2023: Clinical Research
EXOC3L1: A Novel Prognostic Biomarker Correlated with Immune Infiltration in Esophageal Squamous Cell Carcinoma
Zhan-Fei Zhang 12ABCDEFG*DOI: 10.12659/MSM.938512
Med Sci Monit 2023; 29:e938512
Table 1 The correlation between the expression of EXOC3L1 and clinical parameters in ESCC.
| Characteristic | Low expression of EXOC3L1 | High expression of EXOC3L1 | p |
|---|---|---|---|
| Age, n (%) | 1.000 | ||
| ≤60 | 27 (32.9%) | 26 (31.7%) | |
| >60 | 14 (17.1%) | 15 (18.3%) | |
| Gender, n (%) | 0.118 | ||
| Female | 9 (11%) | 3 (3.7%) | |
| Male | 32 (39%) | 38 (46.3%) | |
| Race, n (%) | 0.703 | ||
| Asian | 20 (25%) | 17 (21.2%) | |
| White | 18 (22.5%) | 19 (23.8%) | |
| Others | 2 (2.5%) | 4 (5%) | |
| BMI, n (%) | 0.788 | ||
| ≤25 | 29 (37.2%) | 31 (39.7%) | |
| >25 | 10 (12.8%) | 8 (10.3%) | |
| Smoker, n (%) | 1.000 | ||
| No | 13 (16.5%) | 14 (17.7%) | |
| Yes | 25 (31.6%) | 27 (34.2%) | |
| Drinker, n (%) | 0.599 | ||
| No | 8 (10%) | 11 (13.8%) | |
| Yes | 32 (40%) | 29 (36.2%) | |
| Location, n (%) | 0.791 | ||
| Distal | 21 (25.9%) | 17 (21%) | |
| Mid | 17 (21%) | 20 (24.7%) | |
| Proximal | 3 (3.7%) | 3 (3.7%) | |
| Grade, n (%) | 0.853 | ||
| G1 | 8 (11.1%) | 7 (9.7%) | |
| G2 | 19 (26.4%) | 19 (26.4%) | |
| G3 | 11 (15.3%) | 8 (11.1%) | |
| T Stage, n (%) | 0.977 | ||
| T1–T2 | 18 (22.8%) | 17 (21.5%) | |
| T3–T4 | 23 (29.1%) | 21 (26.6%) | |
| N Stage, n (%) | |||
| N0 | 28 (35.9%) | 18 (23.1%) | |
| N1–N3 | 12 (15.4%) | 20 (25.6%) | |
| M Stage, n (%) | 0.656 | ||
| M0 | 35 (47.9%) | 35 (47.9%) | |
| M1 | 2 (2.7%) | 1 (1.4%) | |
| Stage, n (%) | |||
| I–II | 32 (40.5%) | 22 (27.8%) | |
| III–IV | 9 (11.4%) | 16 (20.3%) |